Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Precision Biosciences (DTIL) Intangibles (2018 - 2025)

Precision Biosciences (DTIL) has disclosed Intangibles for 8 consecutive years, with $985000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Intangibles rose 153.87% to $985000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $985000.0, a 153.87% increase, with the full-year FY2024 number at $622000.0, up 55.5% from a year prior.
  • Intangibles was $985000.0 for Q3 2025 at Precision Biosciences, up from $605000.0 in the prior quarter.
  • In the past five years, Intangibles ranged from a high of $2.1 million in Q3 2021 to a low of $375000.0 in Q2 2024.
  • A 5-year average of $1.2 million and a median of $985000.0 in 2025 define the central range for Intangibles.
  • Peak YoY movement for Intangibles: tumbled 75.84% in 2024, then skyrocketed 153.87% in 2025.
  • Precision Biosciences' Intangibles stood at $2.0 million in 2021, then tumbled by 64.31% to $731000.0 in 2022, then crashed by 45.28% to $400000.0 in 2023, then soared by 55.5% to $622000.0 in 2024, then surged by 58.36% to $985000.0 in 2025.
  • Per Business Quant, the three most recent readings for DTIL's Intangibles are $985000.0 (Q3 2025), $605000.0 (Q2 2025), and $607000.0 (Q1 2025).